Market Cap 49.25M
Revenue (ttm) 0.00
Net Income (ttm) -26.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 103,300
Avg Vol 208,890
Day's Range N/A - N/A
Shares Out 30.98M
Stochastic %K 3%
Beta 1.71
Analysts Strong Sell
Price Target $17.33

Latest News on SKYE

Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 9:58 PM EDT - 13 days ago

Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript


Skye Bioscience to Present at TD Cowen Health Care Conference

Feb 20, 2025, 7:00 AM EST - 5 weeks ago

Skye Bioscience to Present at TD Cowen Health Care Conference


Skye Bioscience Announces Participation in February Conferences

Feb 4, 2025, 7:00 AM EST - 2 months ago

Skye Bioscience Announces Participation in February Conferences


MoneyShow's Best Investment Ideas For 2025: Part 8

Feb 3, 2025, 9:20 AM EST - 2 months ago

MoneyShow's Best Investment Ideas For 2025: Part 8

DELL FNV MNKD MSTR SKE AMSC


Skye Bioscience to Present at J.P. Morgan Healthcare Conference

Dec 19, 2024, 7:00 AM EST - 3 months ago

Skye Bioscience to Present at J.P. Morgan Healthcare Conference


Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 10:36 PM EST - 5 months ago

Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript


Skye Bioscience to Announce Third Quarter 2024 Results

Nov 1, 2024, 7:00 AM EDT - 5 months ago

Skye Bioscience to Announce Third Quarter 2024 Results


Skye: Moving Weight Loss Drugs To The Next Level

Sep 4, 2024, 11:26 AM EDT - 7 months ago

Skye: Moving Weight Loss Drugs To The Next Level


Skye Bioscience Appoints Dr. Karen Smith to Board of Directors

Jul 3, 2024, 7:00 AM EDT - 9 months ago

Skye Bioscience Appoints Dr. Karen Smith to Board of Directors